Literature DB >> 21337704

GPDE: A biological proteomic database for biomarker discovery and evaluation.

Johannes Griss1, Verena Haudek-Prinz, Christopher Gerner.   

Abstract

Clinical proteomics faces extremely complex and variable data. Here, we present an updated version of the Griss Proteomics Database Engine (GPDE): A free biological proteomic database specifically designed for clinical proteomics and biomarker discovery (http://gpde.sourceforge.net). It combines experiments based on investigated cell types thereby supporting customizable biological meta-analyses. Through the new features described here, the GPDE now became a powerful yet easy-to-use tool to support the fast identification and reliable evaluation of biomarker candidates.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Mesh：

Substances：

Year:  2011        PMID： 21337704     DOI： 10.1002/pmic.201000507

Source DB:  PubMed          Journal:  Proteomics        ISSN： 1615-9853            Impact factor:   3.984


  9 in total

1.  Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells.

Authors:  Verena J Haudek-Prinz; Philip Klepeisz; Astrid Slany; Johannes Griss; Anastasia Meshcheryakova; Verena Paulitschke; Goran Mitulovic; Johannes Stöckl; Christopher Gerner
Journal:  J Proteomics       Date:  2012-07-16       Impact factor: 4.044

2.  Plasticity of fibroblasts demonstrated by tissue-specific and function-related proteome profiling.

Authors:  Astrid Slany; Anastasia Meshcheryakova; Agnes Beer; Hendrik Jan Ankersmit; Verena Paulitschke; Christopher Gerner
Journal:  Clin Proteomics       Date:  2014-11-21       Impact factor: 3.988

3.  Phenobarbital induces alterations in the proteome of hepatocytes and mesenchymal cells of rat livers.

Authors:  Philip Klepeisz; Sandra Sagmeister; Verena Haudek-Prinz; Melanie Pichlbauer; Bettina Grasl-Kraupp; Christopher Gerner
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

Review 4.  Identifying novel biomarkers through data mining-a realistic scenario?

Authors:  Johannes Griss; Yasset Perez-Riverol; Henning Hermjakob; Juan Antonio Vizcaíno
Journal:  Proteomics Clin Appl       Date:  2015-01-12       Impact factor: 3.494

5.  Proteome profiling in IL-1β and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis.

Authors:  Thomas Mohr; Verena Haudek-Prinz; Astrid Slany; Johannes Grillari; Michael Micksche; Christopher Gerner
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

Review 6.  In-silico studies in Chinese herbal medicines' research: evaluation of in-silico methodologies and phytochemical data sources, and a review of research to date.

Authors:  D J Barlow; A Buriani; T Ehrman; E Bosisio; I Eberini; P J Hylands
Journal:  J Ethnopharmacol       Date:  2012-02-02       Impact factor: 4.360

7.  Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.

Authors:  Verena Paulitschke; Silke Gruber; Elisabeth Hofstätter; Verena Haudek-Prinz; Philipp Klepeisz; Nikolaus Schicher; Constanze Jonak; Peter Petzelbauer; Hubert Pehamberger; Christopher Gerner; Rainer Kunstfeld
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

8.  MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells.

Authors:  Christoph Campregher; Gerald Schmid; Franziska Ferk; Siegfried Knasmüller; Vineeta Khare; Benedikt Kortüm; Kyle Dammann; Michaela Lang; Theresa Scharl; Andreas Spittler; Andres I Roig; Jerry W Shay; Christopher Gerner; Christoph Gasche
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

9.  Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

Authors:  Verena Paulitschke; Verena Haudek-Prinz; Johannes Griss; Walter Berger; Thomas Mohr; Hubert Pehamberger; Rainer Kunstfeld; Christopher Gerner
Journal:  J Proteome Res       Date:  2013-06-19       Impact factor: 4.466
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.